Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Sarepta Therapeutics

Evaluate

Thumbnail
July 04, 2023

US FDA approval and panel tracker: June 2023

Thumbnail
June 20, 2023

Santhera makes the best of a bad bargain

Article image
Vantage logo
June 01, 2023

US FDA approval and panel tracker: May 2023

Article image
Vantage logo
May 31, 2023

Go or no go? Key FDA decisions for Argenx and Regeneron

Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.

Article image
Vantage logo
May 15, 2023

Approval beckons for Sarepta’s gene therapy

Article image
Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.

Article image
Vantage logo
April 27, 2023

Go or no go? Sarepta’s gene therapy faces scrutiny

SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.

Article image
Vantage logo
March 17, 2023

Sarepta investors fear a panel beating

Article image
Vantage logo
January 17, 2023

Biopharma's stock market winners of 2022 revealed

Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.

Article image
Vantage logo
October 13, 2022

Few safe havens surface in another down quarter for biopharma

Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.

Article image
Vantage logo
October 10, 2022

The gloom deepens for biopharma stocks

With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up